NCT07324746 The Effectiveness of a Herbal Supplement in Osteoarthritis.
| NCT ID | NCT07324746 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Middlesex University |
| Condition | Osteoarthritis (OA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-12-05 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-12-05 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the effectiveness and safety of a combined herbal supplement containing Boswellia serrata, Curcuma longa, and Vitis vinifera in adults with clinically diagnosed knee or hip osteoarthritis. The primary objective is to determine whether the supplement improves osteoarthritis-related symptoms. The supplement will be compared with a placebo. Participants will: * take the supplement and placebo for 4 weeks each, one at a time; * complete validated questionnaires (6 times online) * perform three performance-based physical tests (6 times online) * provide a urine sample
Eligibility Criteria
Inclusion Criteria: * Aged ≥ 18 * Diagnosis of osteoarthritis in knee or hip * Numerical Rating Scale (NRS) ≥ 4 during the most painful movement in the last 24 hours * Lequesne's Functional Index (LFI) score ≥ 7 * Ambulant patient Exclusion Criteria: * Pregnant and breastfeeding * Autoimmune disease such as rheumatoid arthritis, gout, lupus * Joint trauma, joint injury, joint infection, meniscus tear, complete loss of articular cartilage * Expectation of surgery * History of the viscous or corticosteroids injections into affected joints or oral corticosteroids within last 12 months * Allergy to one of the intervention's ingredients or NSAIDs * Peptic ulceration and upper gastrointestinal haemorrhage * High alcohol intake, inability to abstain from alcohol, substance abuse, history of addiction * Tumor, cancer * Abnormal renal or/and hepatic functions or altered blood chemistry * Use of concomitant medication able to interfere with the interventions
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07324746 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Osteoarthritis (OA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07324746 currently recruiting?
Yes, NCT07324746 is actively recruiting participants. Contact the research team at p.x.brodkapedro@mdx.ac.uk for enrollment information.
Where is the NCT07324746 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT07324746 clinical trial?
NCT07324746 is sponsored by Middlesex University. The trial plans to enroll 30 participants.